iTRAQ-Based Proteomics Analysis of Plasma of Myasthenia Gravis Patients Treated with Jia Wei Bu Zhong Yi Qi Decoction

Table 2

Clinical features of MG patients before and after treatment, related treatment methods, and clinical outcomes.

Group	Number	Maximum severity of disease	AchR Ab (nmol/L)	Titin Ab (nmol/L)	Osserman classification	Outcome	Treatment
		Before/after	Before/after	Before/after	Before/after
T1	1	Right blepharoptosis/unchanged	—/—	—/—	I/I	SD	—
	2	Limb weakness, blepharoptosis with blurred vision, weak chewing, dysphagia/unchanged	1.8/4.5	—/—	IIA/IIA	PD	—
	3	Right blepharoptosis with double vision/unchanged	8.5/7.3	—/—	I/I	SD	—
T2	4	Drooping eyes with squint, limb weakness/squint, weak limbs when tired	12.3/9.3	—/—	IIA/IIA	PR	PRE, PYR
	5	Drooping eyelids, limb weakness, mild dysphagia/general fatigue, remaining symptoms disappear	16.3/11.7	—/—	IIA/IIA	PR	PRE, PYR
	6	Blepharoptosis with double vision, limb weakness, mild mastication weakness/double vision, remaining symptoms disappear	—/—	—/—	IIA/I	PR	PRE
T3	7	Blepharoptosis with strabismus and weakness of limbs/strabismus, remaining symptoms disappear	12.3/8.4	—/—	IIA/I	PR	PRE, PYR, and Jia Wei BZYQ decoction
	8	Weakness of limbs, blepharoptosis, mild masticatory weakness, dizziness/eyelids lift weakly when excessive use of the eyes, remaining symptoms disappear	11.3/8.9	8.7/1.9	IIA/I	PR	PYR and Jia Wei BZYQ decoction
	9	Double blepharoptosis, double vision/symptoms disappear	3.6/1.3	3.4/2.2	I/I	PR	PYR and Jia Wei BZYQ decoction

Note: AchR Ab normal ranges: <0.4 nmol/L; Titin Ab normal ranges: < 1.0 nmol/L; “−” = negative; SD = stable disease; PD = progression disease; PR = partial remission; PRE = prednisone; PYR = pyridostigmine.